Early identification of lung cancer patients with venous thromboembolism: development and validation of a risk prediction model

Abstract Introduction Venous thromboembolism(VTE) is a leading cause of death in patients with lung cancer. Furthermore, hospitalization of patients with advanced lung cancer for VTE treatment represents a major economic burden on the national public health resources. Therefore, we performed this pr...

Full description

Bibliographic Details
Main Authors: Wenjuan Di, Haotian Xu, Chunhua Ling, Ting Xue
Format: Article
Language:English
Published: BMC 2023-09-01
Series:Thrombosis Journal
Subjects:
Online Access:https://doi.org/10.1186/s12959-023-00544-w
_version_ 1797451735925522432
author Wenjuan Di
Haotian Xu
Chunhua Ling
Ting Xue
author_facet Wenjuan Di
Haotian Xu
Chunhua Ling
Ting Xue
author_sort Wenjuan Di
collection DOAJ
description Abstract Introduction Venous thromboembolism(VTE) is a leading cause of death in patients with lung cancer. Furthermore, hospitalization of patients with advanced lung cancer for VTE treatment represents a major economic burden on the national public health resources. Therefore, we performed this prospective study to identify clinical biomarkers for the early identification of VTE in lung cancer patients. Methods This prospective study enrolled 158 patients with confirmed lung cancer, including 27 who were diagnosed with VTE within six months of the follow-up after lung cancer diagnosis. Multivariate logistic regression analysis was used to evaluate the diagnostic performancese of all the relevant clinical features and laboratory indicators in identifying lung cancer patients with a higher risk of VTE. A novel risk prediction model was constructed consisting of five clinical variables with the best diagnostic performances and was validated using the receiver operation characteristic(ROC) curves. The diagnostic performances of the new risk prediction model was also compared with the Khorana risk score (KRS) and the Padua risk score (PRS). Results The VTE group of lung cancer patients (n = 27) showed significantly higher serum levels of fibrin degradation products (FDP), D-dimer, thrombomodulin (TM), thrombin-antithrombin-complex (TAT), α2-plasmin inhibitor-plasmin Complex (PIC), and tissue plasminogen activator-plasminogen activator inhibitor complex (t-PAIC) compared to those in the non-VTE group (n = 131). ROC curve analyses showed that the diagnostic efficacy of the new VTE risk prediction model with TM ≥ 9.75 TU/ml, TAT ≥ 2.25ng/ml, t-PAIC ≥ 7.35ng/ml, history of VTE, and ECOG PS score ≥ 2 was superior than the KRS and the PRS in the early identification of lung cancer patients with a higher risk of VTE. Conclusions The new risk prediction model showed significantly high diagnostic efficacy in the early identification of lung cancer patients with a high risk of VTE. The diagnostic efficacy of the new risk prediction model was higher than the KRS and the PRS in this cohort of lung cancer patients.
first_indexed 2024-03-09T14:58:44Z
format Article
id doaj.art-19318008e06844039a29eaf358ec6178
institution Directory Open Access Journal
issn 1477-9560
language English
last_indexed 2024-03-09T14:58:44Z
publishDate 2023-09-01
publisher BMC
record_format Article
series Thrombosis Journal
spelling doaj.art-19318008e06844039a29eaf358ec61782023-11-26T14:00:29ZengBMCThrombosis Journal1477-95602023-09-0121111010.1186/s12959-023-00544-wEarly identification of lung cancer patients with venous thromboembolism: development and validation of a risk prediction modelWenjuan Di0Haotian Xu1Chunhua Ling2Ting Xue3Department of Pulmonary and Critical Care Medicine, Kunshan Hospital of Traditional Chinese MedicineDepartment of Pulmonary and Critical Care Medicine, The First Hospital Affiliated of Soochow UnversityDepartment of Pulmonary and Critical Care Medicine, The First Hospital Affiliated of Soochow UnversityDepartment of Pulmonary and Critical Care Medicine, The First Hospital Affiliated of Soochow UnversityAbstract Introduction Venous thromboembolism(VTE) is a leading cause of death in patients with lung cancer. Furthermore, hospitalization of patients with advanced lung cancer for VTE treatment represents a major economic burden on the national public health resources. Therefore, we performed this prospective study to identify clinical biomarkers for the early identification of VTE in lung cancer patients. Methods This prospective study enrolled 158 patients with confirmed lung cancer, including 27 who were diagnosed with VTE within six months of the follow-up after lung cancer diagnosis. Multivariate logistic regression analysis was used to evaluate the diagnostic performancese of all the relevant clinical features and laboratory indicators in identifying lung cancer patients with a higher risk of VTE. A novel risk prediction model was constructed consisting of five clinical variables with the best diagnostic performances and was validated using the receiver operation characteristic(ROC) curves. The diagnostic performances of the new risk prediction model was also compared with the Khorana risk score (KRS) and the Padua risk score (PRS). Results The VTE group of lung cancer patients (n = 27) showed significantly higher serum levels of fibrin degradation products (FDP), D-dimer, thrombomodulin (TM), thrombin-antithrombin-complex (TAT), α2-plasmin inhibitor-plasmin Complex (PIC), and tissue plasminogen activator-plasminogen activator inhibitor complex (t-PAIC) compared to those in the non-VTE group (n = 131). ROC curve analyses showed that the diagnostic efficacy of the new VTE risk prediction model with TM ≥ 9.75 TU/ml, TAT ≥ 2.25ng/ml, t-PAIC ≥ 7.35ng/ml, history of VTE, and ECOG PS score ≥ 2 was superior than the KRS and the PRS in the early identification of lung cancer patients with a higher risk of VTE. Conclusions The new risk prediction model showed significantly high diagnostic efficacy in the early identification of lung cancer patients with a high risk of VTE. The diagnostic efficacy of the new risk prediction model was higher than the KRS and the PRS in this cohort of lung cancer patients.https://doi.org/10.1186/s12959-023-00544-wLung cancerVenous thromboembolismBiomarkerRisk factorRisk prediction model
spellingShingle Wenjuan Di
Haotian Xu
Chunhua Ling
Ting Xue
Early identification of lung cancer patients with venous thromboembolism: development and validation of a risk prediction model
Thrombosis Journal
Lung cancer
Venous thromboembolism
Biomarker
Risk factor
Risk prediction model
title Early identification of lung cancer patients with venous thromboembolism: development and validation of a risk prediction model
title_full Early identification of lung cancer patients with venous thromboembolism: development and validation of a risk prediction model
title_fullStr Early identification of lung cancer patients with venous thromboembolism: development and validation of a risk prediction model
title_full_unstemmed Early identification of lung cancer patients with venous thromboembolism: development and validation of a risk prediction model
title_short Early identification of lung cancer patients with venous thromboembolism: development and validation of a risk prediction model
title_sort early identification of lung cancer patients with venous thromboembolism development and validation of a risk prediction model
topic Lung cancer
Venous thromboembolism
Biomarker
Risk factor
Risk prediction model
url https://doi.org/10.1186/s12959-023-00544-w
work_keys_str_mv AT wenjuandi earlyidentificationoflungcancerpatientswithvenousthromboembolismdevelopmentandvalidationofariskpredictionmodel
AT haotianxu earlyidentificationoflungcancerpatientswithvenousthromboembolismdevelopmentandvalidationofariskpredictionmodel
AT chunhualing earlyidentificationoflungcancerpatientswithvenousthromboembolismdevelopmentandvalidationofariskpredictionmodel
AT tingxue earlyidentificationoflungcancerpatientswithvenousthromboembolismdevelopmentandvalidationofariskpredictionmodel